Opendata, web and dolomites
  1. home
  2. trasparenza
  3. open h2020
  4. respiratory-immunodx

Respiratory-ImmunoDx SIGNED

Clinical validation of host biomarker signature for distinguishing bacterial versus viral lower respiratory tract infections (LRTI) in adults at the point-of-need

Total Cost €

0

EC-Contrib. €

0

Partnership

0

Views

0
 Outcomes and results

 Respiratory-ImmunoDx project word cloud

Explore the words cloud of the Respiratory-ImmunoDx project. It provides you a very rough idea of what is the project "Respiratory-ImmunoDx" about.

viral    strategy    1100    hours    significantly    validating    globally    prospective    aligned    lower    validated    46    antibiotic    emergence    versus    signature    diagnosis    incidents    infection    life    immunoxpert    tools    memed    health    validate    clinical    light    protein    death    innovative    impactful    measured    reducing    population    pon    blood    gt    tests    risk    approved    1000    burden    million    give    slowing    immunodx    instrument    adult    accurate    resistant    adoption    quality    tract    annually    outperforming    setting    worldwide    market    complications    ageing    adults    respiratory    accurately    comprising    lrtis    physicians    disease    lab    older    mortality    device    obtain    goals    biomarker    patients    trade    accelerated    immunoxperttm    distinguished    3rd    clinically    enrolling    prohibit    performed    diagnostic    clearance    underuse    trail    infections    treatment    initially    billion    profoundly    drop    regulatory    lrti    actionable    sme    bacteria    bacterial    pioneering    ivd    insufficient    guiding    point    public    overuse    host    ce    managed    adverse    outpatient    subpopulation   

Project "Respiratory-ImmunoDx" data sheet

The following table provides information about the project.

Coordinator		 MEMED DIAGNOSTICS LTD 

Organization address
address: NAHUM HETH STREET 5
city: TIRAT CARMEL
postcode: 39120
website: www.me-med.com

contact info
title: n.a.
name: n.a.
surname: n.a.
function: n.a.
email: n.a.
telephone: n.a.
fax: n.a.
 Coordinator Country Israel [IL]
 Project website http://www.me-med.com/html5/
 Total cost 2˙935˙000 €
 EC max contribution 2˙935˙000 € (100%)
 Programme 1. H2020-EU.2.1.3. (INDUSTRIAL LEADERSHIP - Leadership in enabling and industrial technologies - Advanced materials)
2. H2020-EU.3.1.3. (Treating and managing disease)
 Code Call H2020-SMEINST-2-2015
 Funding Scheme SME-2
 Starting year 2015
 Duration (year-month-day) from 2015-12-01   to  2018-11-30

 Partnership

Take a look of project's partnership.

# participants  country  role  EC contrib. [€] 
1    MEMED DIAGNOSTICS LTD IL (TIRAT CARMEL) coordinator 2˙935˙000.00

Map

 Project objective

Lower respiratory tract infection (LRTI) is the 3rd leading cause of death worldwide. In the EU 30 million incidents occur annually, with associated costs of €46 billion. Older adults are at higher risk of developing LRTI, and therefore, in light of Europe's ageing population, the disease burden will increase. Since most adult LRTIs are managed in the outpatient setting, innovative diagnostic tools for guiding treatment at the point-of-need (PON), would be impactful. MeMed identified a host-biomarker signature comprising a novel viral induced protein called TRAIL. Based on this signature, MeMed developed a test called ImmunoXpertTM (CE-IVD approved). In a prospective study with >1000 patients, ImmunoXpert™ accurately distinguished viral versus bacterial infections, significantly outperforming traditional tests. Two factors prohibit wide adoption of ImmunoXpert for managing LRTI adult patients: i) insufficient clinical evidence validating the signature in this subpopulation and ii) ImmunoXpert™ is performed in a lab and requires 2 hours. To address this we propose:

• To clinically validate the biomarker signature for accurate diagnosis of viral versus bacterial LRTI, in a prospective study enrolling 1100 adult EU patients at the PON

• To develop, validate and obtain EU regulatory clearance for a new PON device (to be called ImmunoDx™) that rapidly measures the signature from a drop of blood

These objectives are highly aligned with the SME instrument goals and MeMed’s strategy. They will allow a pioneering test to achieve accelerated market adoption, initially in Europe and then globally. The validated signature, measured using ImmunoDx™, will give physicians, accurate and actionable information at the PON. This test has potential to profoundly impact patients' quality of life by reducing adverse effects due to antibiotic overuse; reducing complications and mortality due to underuse; and slowing the emergence of antibiotic resistant bacteria, a major public health

 Deliverables

List of deliverables.
A dedicated website for OBSERVER and ImmunoDxâ„¢ Websites, patent fillings, videos etc. 2019-05-31 17:19:04
Presenting at infectious disease conference Websites, patent fillings, videos etc. 2019-05-31 17:19:02

Take a look to the deliverables list in detail:  detailed list of Respiratory-ImmunoDx deliverables.

Are you the coordinator (or a participant) of this project? Plaese send me more information about the "RESPIRATORY-IMMUNODX" project.

For instance: the website url (it has not provided by EU-opendata yet), the logo, a more detailed description of the project (in plain text as a rtf file or a word file), some pictures (as picture files, not embedded into any word file), twitter account, linkedin page, etc.

Send me an  email (fabio@fabiodisconzi.com) and I put them in your project's page as son as possible.

Thanks. And then put a link of this page into your project's website.

The information about "RESPIRATORY-IMMUNODX" are provided by the European Opendata Portal: CORDIS opendata.

More projects from the same programme (H2020-EU.2.1.3.;H2020-EU.3.1.3.)

PNEUMOSIP (2015)

PNEUMOSIP

Read More  

Respiratory-ImmunoDx (2015)

Clinical validation of host biomarker signature for distinguishing bacterial versus viral lower respiratory tract infections (LRTI) in adults at the point-of-need

Read More  

MPIPETrace (2015)

Clinical performance validation of a novel biomarker for quantitative imaging of coronary artery disease.

Read More